Critical Comparison: Palatin Technologies (PINK:PTNT) & Galera Therapeutics (NASDAQ:GRTX)

Volatility and Risk

Galera Therapeutics has a beta of 1.74, meaning that its share price is 74% more volatile than the S&P 500. Comparatively, Palatin Technologies has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500.

Institutional & Insider Ownership

50.8% of Galera Therapeutics shares are owned by institutional investors. Comparatively, 11.5% of Palatin Technologies shares are owned by institutional investors. 12.9% of Galera Therapeutics shares are owned by company insiders. Comparatively, 7.1% of Palatin Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Galera Therapeutics and Palatin Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Galera Therapeutics	N/A	N/A	-99.34%
Palatin Technologies	N/A	N/A	-365.57%

Earnings and Valuation

This table compares Galera Therapeutics and Palatin Technologies”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galera Therapeutics	N/A	N/A	-$59.08 million	($0.10)	-0.47
Palatin Technologies	$4.49 million	32.44	-$29.74 million	($1.55)	-3.61

Palatin Technologies has higher revenue and earnings than Galera Therapeutics. Palatin Technologies is trading at a lower price-to-earnings ratio than Galera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Galera Therapeutics beats Palatin Technologies on 6 of the 8 factors compared between the two stocks.

About Galera Therapeutics

Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy. It also develops rucosopasem manganese (rucosopasem) to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.

About Palatin Technologies

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.